[1]
Beretta, G.L.; Binaschi, M.; Zagni, E.; Capuani, L.; Capranico, G. Tethering a type IB topoisomerase to a DNA site by enzyme fusion to a heterologous site-selective DNA-binding protein domain. Cancer Res., 1999, 59(15), 3689-3697.
[2]
Beretta, G.L.; Benedetti, V.; Cossa, G.; Assaraf, Y.G.A.; Bram, E.; Gatti, L.; Corna, E.; Carenini, N.; Colangelo, D.; Howell, S.B.; Zunino, F.; Perego, P. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem. Pharmacol., 2010, 79(8), 1108-1117.
[http://dx.doi.org/10.1016/j.bcp.2009.12.002]
[http://dx.doi.org/10.1016/j.bcp.2009.12.002]
[3]
Perego, P.; Gatti, L.; Beretta, G.L. The ABC of glycosylation. Nat. Rev. Cancer, 2010, 10(7), 523.
[http://dx.doi.org/10.1038/nrc2789-c1]
[http://dx.doi.org/10.1038/nrc2789-c1]
[4]
Perego, P.; Cossa, G.; Tinelli, S.; Corna, E.; Carenini, N.; Gatti, L.; De Cesare, M.; Ciusani, E.; Zunino, F.; Luison, E.; Canevari, S.; Zaffaroni, N.; Beretta, G.L. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem. Pharmacol., 2012, 83(1), 27-36.
[http://dx.doi.org/10.1016/j.bcp.2011.09.021]
[http://dx.doi.org/10.1016/j.bcp.2011.09.021]
[5]
Beretta, G.L.; Folini, M.; Cavalieri, F.; Yan, Y.; Fresch, E.; Kaliappan, S.; Hasenöhrl, C.; Richardson, J.J.; Tinelli, S.; Fery, A.; Caruso, F.; Zaffaroni, N. Unravelling “off-target” effects of redox-active polymers and polymer multilayered capsules in prostate cancer cells. Nanoscale, 2015, 7(14), 6261-6270.
[http://dx.doi.org/10.1039/c4nr07240e]
[http://dx.doi.org/10.1039/c4nr07240e]
[6]
Cavalieri, F.; Beretta, G.L.; Cui, J.; Braunger, J.A.; Yan, Y.; Richardson, J.J.; Tinelli, S.; Folini, M.; Zaffaroni, N.; Caruso, F. Redox-sensitive PEG-polypeptide nanoporous particles for survivin silencing in prostate cancer cells. Biomacromolecules, 2015, 16(7), 2168-2178.
[http://dx.doi.org/10.1021/acs.biomac.5b00562]
[http://dx.doi.org/10.1021/acs.biomac.5b00562]
[7]
Zaffaroni, N.; Beretta, G.L. Resveratrol and prostate cancer: the power of phytochemicals. Curr. Med. Chem., 2021, 28(24), 4845-4862.
[http://dx.doi.org/10.2174/0929867328666201228124038]
[http://dx.doi.org/10.2174/0929867328666201228124038]
[8]
Stamatakos, S.; Beretta, G.L.; Vergani, E.; Dugo, M.; Corno, C.; Corna, E.; Tinelli, S.; Frigerio, S.; Ciusani, E.; Rodolfo, M.; Perego, P.; Gatti, L. Deregulated FASN expression in BRAF inhibitor resistant melanoma cells unveils new targets for drug combinations. Cancers (Basel), 2021, 13(9), 2284.
[http://dx.doi.org/10.3390/cancers13092284]
[http://dx.doi.org/10.3390/cancers13092284]
[9]
Vergani, E.; Beretta, G.L.; Aloisi, M.; Costantino, M.; Corno, C.; Frigerio, S.; Tinelli, S.; Dugo, M.; Accattatis, F.M.; Granata, A.; Arnaboldi, L.; Rodolfo, M.; Perego, P.; Gatti, L. Targeting of the lipid metabolism impairs resistance to BRAF kinase inhibitor in melanoma. Front. Cell Dev. Biol., 2022, 10, 927118.
[http://dx.doi.org/10.3389/fcell.2022.927118]
[http://dx.doi.org/10.3389/fcell.2022.927118]
[10]
Bhangu, S.K.; Fernandes, S.; Beretta, G.L.; Tinelli, S.; Cassani, M.; Radziwon, A.; Wojnilowicz, M.; Sarpaki, S.; Pilatis, I.; Zaffaroni, N.; Forte, G.; Caruso, F.; Ashokkumar, M.; Cavalieri, F. Transforming the chemical structure and bio-nano activity of doxorubicin by ultrasound for selective killing of cancer cells. Adv. Mater., 2022, 34(13), e2107964.
[http://dx.doi.org/10.1002/adma.202107964]
[http://dx.doi.org/10.1002/adma.202107964]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
